David Grieve

David Grieve is a Professor and Dean of Internationalisation at Queen's University Belfast's School of Medicine, Dentistry and Biomedical Sciences. His research focuses on cardiovascular biology, pathophysiology, and pharmacology, with particular expertise in oxidative stress, diabetes-related vascular dysfunction, and endothelial progenitor cells. He employs molecular biology techniques to investigate cardiovascular remodeling and therapeutic interventions.

Prof. Grieve's research interests include:

• Mechanisms of cardiovascular remodeling and dysfunction
• Role of oxidative stress and NADPH oxidases in disease
• Novel peptide hormones and endothelial progenitor cells
• Diabetes-induced cardiovascular complications
• Therapeutic modulation of vascular repair mechanisms

His recent publications demonstrate strong focus on diabetic cardiomyopathy, endothelial dysfunction, and novel therapeutic approaches. The research shows consistent emphasis on translational applications, with numerous studies exploring clinical interventions for cardiovascular diseases. Trends include increased focus on epigenetic regulation, cellular senescence, and precision targeting of molecular pathways.

Scientific awards and honors:

• International Society for Heart Research Young Investigator Award
• Medical Research Council UK New Investigator Research Grant
• Multiple presentation prizes from cardiovascular conferences
• Over £7M in competitive research funding

Prof. Grieve has supervised 33 PhD students, including 9 current candidates, and actively contributes to undergraduate and postgraduate teaching in biomedical sciences and experimental medicine. He established a research program investigating cardiovascular adaptations in disease states and leads collaborations on international research projects.

He directs laboratory facilities for cardiovascular physiology research and collaborates extensively through the British Heart Foundation projects network. Current work explores novel treatments for ischemic diseases and diabetic complications at the molecular level.